Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive morphologic variant of chondrosarcoma. It is composed of a low grade chondrosarcoma and a high grade non-cartilagenous sarcomatous component. Due to the aggressive nature of the disease, its prognosis is poor.
Biomarker and diagnostic research for dedifferentiated chondrosarcoma has been reported in the published literature.
4 clinical trials registered. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE2. Research is primarily sponsored by academic and government institutions.
36 publications have been identified in PubMed for dedifferentiated chondrosarcoma. Research spans Case Report / Case Series (36%), Clinical Trial Publication (17%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:29 AM UTC
36%
Clinical study results | 6 | 17% |
Disease patterns and progression | 5 | 14% |
Testing and diagnosis research | 4 | 11% |
Laboratory research | 3 | 8% |
Other research | 2 | 6% |
Research summaries | 2 | 6% |
New treatment approaches | 1 | 3% |
Assi T (2026). [PMID: 41930458](https://pubmed.ncbi.nlm.nih.gov/41930458/). *Immunotherapy*. [Other]
Gristwood K (2026). [PMID: 41500232](https://pubmed.ncbi.nlm.nih.gov/41500232/). *Bioconjugate chemistry*. [Case Report / Case Series]
Kaur D (2026). [PMID: 42068107](https://pubmed.ncbi.nlm.nih.gov/42068107/). *Diagn Cytopathol*. [Case Report / Case Series]
Kawasaki T (2026). [PMID: 42200018](https://pubmed.ncbi.nlm.nih.gov/42200018/). *Front Oncol*. [Clinical Trial Publication]
Yedla SVV (2026). [PMID: 42266314](https://pubmed.ncbi.nlm.nih.gov/42266314/). *Cureus*. [Case Report / Case Series]
Remiszewski P (2026). [PMID: 41895355](https://pubmed.ncbi.nlm.nih.gov/41895355/). *Crit Rev Oncol Hematol*. [Review / Meta-Analysis]
Saisuwan K (2025). [PMID: 40459681](https://pubmed.ncbi.nlm.nih.gov/40459681/). *Human cell*. [Epidemiology / Natural History]
Montoya-Cerrillo DM (2025). [PMID: 40944348](https://pubmed.ncbi.nlm.nih.gov/40944348/). *Genes, chromosomes & cancer*. [Gene Therapy / Novel Therapeutics]
Masunaga T (2025). [PMID: 40079610](https://pubmed.ncbi.nlm.nih.gov/40079610/). *SICOT-J*. [Epidemiology / Natural History]
Palmerini E (2025). [PMID: 39540661](https://pubmed.ncbi.nlm.nih.gov/39540661/). *Cancer*. [Other]